Patients diagnosed with cancer who were scheduled for or received anthracycline-based chemotherapy cancer, anthracycline-based chemotherapy, HFA-ICOS risk score, Artificial intelligence-enabled electrocardiography, left ventricular systolic dysfunction
Conditions
Interventions
Patients with active malignancies (both solid tumors and hematologic cancers) who were scheduled for or receiving anthracycline-based chemotherapy.
Health Services Research
Cancer Therapy-Related Cardiac Dysfunction
Sponsors
Prof. Arintaya Phrommintikul, M.D.
Eligibility
Sex/Gender
All
Age
20 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age 20 years or older 2. Confirmed diagnosis of underlying active cancer (solid or hematological neoplasia) 3. Planned or initiated treatment with cardiotoxic agents, specifically Anthracycline 4. Availability of a baseline 12-lead ECG tracing recorded within 30 days prior to the first dose of cardiotoxic therapy. 5. Availability of a baseline LVEF measurement 6. Availability of clinical follow-up data, including serial LVEF assessments, up to 12 months post-treatment initiation or until the time of a CTRCD event, non-cardiac death, or loss to follow-up
Exclusion criteria
Exclusion criteria: 1. Known pre-existing Left Ventricular Systolic Dysfunction (LVEF less than 50%) at baseline. 2. Established clinical heart failure or cardiomyopathy at baseline.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| LVEF reduction drop less than 10% from baseline 12 month percent | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of major adverse cardiac events (MACE) 12 month event,Incidence of the individual endpoint of major adverse cardiac events 12 month event | — |
Countries
Thailand
Contacts
Public ContactArintaya Phrommintikul
Faculty of Medicine, Chiang Mai University
Outcome results
None listed